Vancouver, British Columbia–(Newsfile Corp. – May 10, 2023) – Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) – Defence Therapeutics is a Canadian biotech company that develops immune-related cancer therapies with proprietary technology. With three clinical trials scheduled by year-end, the company offers growth potential for investors. Defence is seeking to license its technology to enhance other companies’ products in the pharmaceutical industry.
Cannot view this video? Visit:
https://www.b-tv.com/post/cse-dtc-investor-alert-defence-therapeutics-developing-immune-related-therapies-for-cancer-treatment-btv-30sec
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF)
https://defencetherapeutics.com/
About BTV:
BTV-Business Television is Canada’s longest running business show. With Hosts Taylor Thoen and Jessica Katrichak, BTV features emerging companies across the country to bring viewers investment opportunities. BTV also produces News Alerts and branding/ awareness spots for issuers broadcast on BNN Bloomberg, Fox Business News, Bloomberg TV US and Bloomberg Terminals. www.b-tv.com
BTV – Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/165568
Introduction by Lou Wallace, Written by Rune Sørgård Anyone who has lit a process-car shot…
PALO ALTO, CA / ACCESS Newswire / September 30, 2026 / Bioz, Inc., the leading…
Ojai Vision Recovery System pairs air compression, heat, vibration and Bluetooth® audio in a full-blackout…
New studio helps game teams scale engineering, art, QA, production, LiveOps, and player support around…
Configurable waveguide display gives defense and security customers a significant jumpstart for their custom wearable systemsROCHESTER,…
Five days of programming will span AI upskilling, health innovation, govtech, entrepreneurship, executive leadership and…